ADCT-402 is being developed for the treatment of CD19-expressing non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).

A Phase I clinical trial with ADCT-402 in patients with relapsed or refractory NHL is open for enrolment and ongoing (NCT02669017). To read more about NHL, click here.

A Phase I clinical trial with ADCT-402 in patients with B-ALL is open for enrolment and ongoing (NCT02669264). To read more about ALL, click here.

To read more about our clinical trials with ADCT-402, click here.